latest news releases from the newsroom
Scott+Scott, LLC Notifies Investors of Filing Deadline: Five Business Days to Move for Lead Plaintiff Appointment in Action Against Micron Technology -- MU
COLCHESTER, Conn., April 19, 2006 (PRIMEZONE) -- Scott+Scott, LLC notifies investors that five business days remain in which to request that the Court appoint them as lead plaintiff in a securities-fraud action against Micron Technology, Inc. (NYSE:MU) ("Micron" or the "Company"). Scott+Scott filed a complaint against the Company and insiders on April 13, 2006, on behalf of MU securities purchasers from February 24, 2001, through February 13, 2003, inclusive (the "Class Period"), for securities law violations. Defendant Micron manufactures and markets semiconductor devices worldwide, including a series of dynamic random access memory ("DRAM") products, which provide data storage and retrieval in various electronic applications, such as personal computers, mobile phones, flash memory cards and MP3 players.
Ever-Glory International Group Inc.
Ever-Glory Passes Evaluation of Abercrombie & Fitch and Signs New Contract
LOS ANGELES, April 19, 2006 (PRIMEZONE) -- Ever-Glory International Group (OTCBB:EGLY) announced today the company has passed the evaluation of Abercrombie & Fitch's Product Quality Standard to become its producer. The production orders were signed through an agent and valued at over $500,000. Ever-Glory's reputation for quality products and responsible business practices are becoming firmly established throughout the apparel industry as deals with more top-tier apparel companies are in discussion.
Emulex Announces Acquisition of Aarohi Communications
COSTA MESA and SAN JOSE, Calif., April 19, 2006 (PRIMEZONE) -- Emulex Corporation (NYSE:ELX), the most trusted name in storage networking connectivity, and Aarohi Communications announced today the two companies have signed a definitive agreement for Emulex to acquire Aarohi, a leading supplier of intelligent data center networking components and software.
Discovery Laboratories, Inc.
Discovery Labs Secures $50 Million Committed Equity Financing Facility
WARRINGTON, Pa., April 19, 2006 (PRIMEZONE) -- Discovery Laboratories, Inc. (Nasdaq:DSCO), has entered into a new Committed Equity Financing Facility (CEFF) with Kingsbridge Capital Limited, a private investment group, in which Kingsbridge has committed to provide up to $50 million of capital to support Discovery Labs' future growth through the purchase of newly issued shares of its common stock. Upon effectiveness of the new CEFF, as described below, the Company's 2004 CEFF, which presently has capital of up to $47.6 million available, will automatically terminate.
PSB Group, Inc.
PSB Group, Inc. Announces First-Quarter Earnings
MADISON HEIGHTS, Mich., April 19, 2006 (PRIMEZONE) -- PSB Group, Inc., (OTCBB:PSBG), the bank holding company for Peoples State Bank, a Michigan state-chartered bank with offices in Wayne, Oakland, Macomb and Genesee Counties, today announced net income for the first quarter of 2006 was $735,000 or $.24 per average outstanding share, compared to $887,000, or $.29 per average outstanding share in the first quarter of 2005.
Advanced Lighting Technologies, Inc
Venture Lighting Expands to Second Facility Near Cleveland, Increases Metal Halide Lamp and Ballast Production at Chennai, India Plant
SOLON, Ohio, April 19, 2006 (PRIMEZONE) -- Advanced Lighting Technologies, Inc. announced today that its Venture Lighting International division, the world's largest dedicated producer of state-of-the-art metal halide lamp and ballast systems for wide-ranging outdoor and indoor applications, is expanding into a new, second facility southeast of Cleveland. Wayne Hellman, founder and chief executive officer of Advanced Lighting, made the announcement.
Pathogenics, Inc. Licenses Worldwide Rights to Novel Anti-Infective Compound for Ophthalmological Use
HINGHAM, Mass., April 19, 2006 (PRIMEZONE) -- Pathogenics, Inc. (Other OTC:PTGN) today announced that it has licensed to Acuity Pharmaceuticals, Inc. the exclusive worldwide rights to N-Chlorotaurine, or NCT, a novel anti-infective compound for the treatment of ophthalmic infections and other diseases. Pathogenics retains the exclusive worldwide rights to NCT for all indications other than ophthalmic applications. Acuity is paying Pathogenics an up-front licensing fee and minimum annual license fees, as well as potentially multiple millions of dollars worth of development milestones and royalties. Further details of the agreement were not disclosed.